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Abstract
Background: The β-amyloid precursor protein (APP) is sequentially cleaved by the β- and then
γ-secretase to generate the amyloid β-peptides Aβ40 and Aβ42. Increased Aβ42/Aβ40 ratios
trigger amyloid plaque formations in Alzheimer's disease (AD). APP binds to APP-BP1, but the
biological consequence is not well understood.
Results: We report that when the endogenous APP-BP1 was suppressed by small interfering
RNAs (siRNAs), cell-associated Aβ42 was dramatically increased in APP695 expressing primary
neurons. The accumulation of Aβ42 was accompanied by significant increases in APP and APP-CTF
in APP-BP1 siRNA expressing neurons. In contrast, APP-BP1 overexpression in primary neurons
significantly decreased the levels of Aβ and endogenous APP but not APLPs. We also investigated
the potential mechanism of APP-BP1-mediated APP processing. APP-BP1 co-precipitated with
Presenilin-1 (PS1) in native rat brain extracts, co-migrated with the γ-secretase components in
brain membrane extracts in glycerol gradient centrifugation, and colocalized in primary neurons.
Further, the endogenous PS1-CTF was significantly downregulated by APP-BP1 expression.
Conclusion: Our data suggest that APP-BP1 may inhibit Aβ42 production by interacting with PS1
under physiological conditions.
Background
The amyloid precursor protein (APP) binding protein-
1(APP-BP1) is the regulatory subunit of the activating
enzyme for the small ubiquitin-like protein Nedd8 [1,2].
APP-BP1 is homologous to the amino-terminus of E1,
and binds to Uba3 which is homologous to the carboxyl
terminus of E1 and contains the catalytic cysteine residue.
APP-BP1 forms a heterodimer with Uba3, and together
activates the small ubiquitin-like protein Nedd8 [3].
When Nedd8 is activated, it covalently modifies (ned-
dylates) Cullin family members [4]. Cullins are the subu-
nit of a class of ubiquitin E3 ligase complex. Neddylated
Cullins may become transiently stable, resulting in
enhanced ubiquitin ligase activity and increased degrada-
tion of target proteins [5].
At the cellular level, neddylation regulates cell cycle pro-
gression at two checkpoints – APP-BP1 inhibits entry into
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mitosis in dividing cells [2,6], presumably by neddylation
of different Cullin proteins. Loss of APP-BP1 function in
the Chinese hamster liver cell line, ts41 cells, results in the
accumulation of cells in the S and G1 phases of the cell
cycle [6]. Expressing human APP-BP1 can rescue the cell
cycle defect in ts41 cells at the non-permissive tempera-
ture [2]. Knocking out the activation subunit of the Nedd8
activating enzyme, Uba3, leads to embryonic lethality at
the peri-implantation stage [7]. Therefore, the APP-BP1-
mediated neddylation is critical for somatic cell survival.
The function of APP-BP1 in the brain is not well under-
stood. In primary neurons, overexpression of APP-BP1
triggers DNA synthesis followed by apoptosis [2,8]. In
Alzheimer's disease (AD), the modified APP-BP1 (about
65 kDa) is elevated in the Triton-insoluble and SDS-solu-
ble fractions [8]. Neddylation appears to be activated in
AD hippocampal neurons [8]. Based on these data, we
hypothesized before that APP-BP1 was detrimental to
neuronal survival. However, APP-BP1 mRNAs are highly
expressed in brain hippocampal pyramidal and granule
cells [1]. Nedd8 and APP-BP1 proteins are also expressed
in hippocampal neurons [8]. The hippocampal brain
structure is critical for learning and memory and is
severely damaged in AD. These observations suggest that
APP-BP1 may have a regulatory function in neurons in
physiological conditions.
APP-BP1 binds to the cytoplasmic domain of APP. Data
from primary neuronal cultures and drosophila genetics
suggest that APP signaling is at least partially transmitted
through APP-BP1 [8,9]. APP undergoes cleavage within
the membrane spanning region by the γ-secretase to gen-
erate Aβ. Presenilin is an integral component of the γ-
secretase complex [10]. Presenilin-deficiency abolishes
most Aβ genesis if not all of it [11-13]. In addition to the
interactions with APP, both APP-BP1 and PS1 regulate β-
catenin levels. For example, knocking out the activation
subunit of the Nedd8 activating enzyme, Uba3 [7], or PS1
[14] in mice both result in β-catenin accumulation. Based
on these intricate connections, here we examined if APP-
BP1 played a role in APP processing. We reported that
suppression of APP-BP1 by small interfering RNAs (siR-
NAs) in primary neurons induced a dramatic increase in
Aβ42 production accompanied by increased levels of APP
and APP-CTFs. We examined the possible mechanisms of
APP-BP1-mediated Aβ42 inhibition and discovered that
APP-BP1 expression facilitated PS1-CTF degradation.
Results
APP-BP1 co-precipitated with PS1 in rat brain extracts
PS1 and APP-BP1 both mediate the degradation of β-cat-
enin and interact with the Aβ precursor protein APP.
These connections indicated that APP-BP1 might also
interact with PS1. In these experiments, rat brain PS1 was
precipitated with the rabbit PS1 antibody which was
raised against the PS1 loop region (AB5308, Chemicon).
The immunoprecipitates were transferred to the nitrocel-
lulose membrane and blotted with the rabbit anti-APP-
BP1 antibody, BP339. The anti-PS1 antibody specifically
pulled down APP-BP1 (Fig. 1A, top). In the controls
where no antibody or an antibody against cyclin B1 was
added to the lysate, no APP-BP1 was specifically co-pre-
cipitated. Probing the same blots with anti-nicastrin
revealed that nicastrin was also in the same complex (Fig.
1A, bottom).
In reciprocal co-ip experiments, APP-BP1 was precipitated
with BP339 from membrane fractions extracted from rat
brains (Fig. 1B). PS1-full length (FL) and PS1-CTF probed
by the anti-PS1 (AB5308) co-precipitated with APP-BP1.
PS1-NTF was blotted by the PS1-NTF antibody (gift from
Huaxi Xu). Fig. 1B shows that PS1 co-precipitated with
APP-BP1. Similarly, nicastrin was present in the APP-BP1
immunoprecipitate as identified by anti-nicastrin blot.
Based on the whole cell extracts loaded onto the same
gels, we estimated that about 1% of PS1 was associated
with APP-BP1. Interestingly, also about 1% of APP-BP1
was precipitated with PS1. Together, these co-ip experi-
ments suggest that APP-BP1 is associated with the γ-secre-
tase complex, and mutagenesis may be needed to
determine the molecular interactions between APP-BP1
and the components of the γ-secretase complex.
APP-BP1 co-migrated with PS1 in glycerol gradient
APP-BP1 mainly exists as a cytoplasmic protein about 59
kDa in crude cell fractionation analyses (Chen, unpub-
lished observation). A small percentage of APP-BP1 that
migrates at about 65 kDa can be isolated by sucrose gradi-
ent centrifugation from the Triton-insoluble and SDS-sol-
uble brain protein extracts which are also enriched with
lipids [8]. APP-BP1 post-translational modifications may
allow it to interact with membrane proteins. Lipid rafts
may be the site of Aβ42 genesis [15]. Lipid rafts also con-
tain the fully assembled γ-secretase complex [16].
The PS1-containing γ-secretase complex can also be iso-
lated from membrane fractions on a glycerol gradient
[17], suggesting that the fractions from the sucrose and
glycerol gradient centrifugations have overlapping resolu-
tions. Here, we used glycerol gradient to determine if APP-
BP1 co-migrated with PS1 in brain membrane protein
extracts (Fig. 1C). Fraction 1 represented the top of the
gradient. APP-BP1 co-migrated with PS1 after glycerol gra-
dient centrifugation in fractions 2 to 4, which also con-
sisted of another γ-secretase component, nicastrin. Note
that the 65 kDa APP-BP1 specifically migrated with PS1 in
the glycerol gradient, similar to what we previously
observed in the lipid-enriched Triton-insoluble and SDS-Page 2 of 12
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[8]. The fainter band right below the major band of APP-
BP1 in fractions 2 and 3 was the non-modified 59 kDa
APP-BP1. This 59 kDa APP-BP1 was probably reduced
from the 65 kDa form due to frequent handling judging
from our experience of working with these samples. The
distribution of β-catenin was more spread out in the glyc-
erol gradient with fractions 4 to 6 containing the highest
amount (Fig. 1C). The distribution of PS1 was similar to
those reported in glycerol gradients under similar condi-
tions [18]. A PS1-CTF-specific antibody, PS1-C [19], also
recognized the same band about 22 kDa in Fig. 1C (Fig.
1D). Together, our data suggested that the modified APP-
BP1 present in a lipid-enriched membrane fraction might
modulate PS1 γ-secretase activity. We are currently analyz-
ing the type of modification that APP-BP1 may undergo
for membrane targeting.
APP-BP1 and PS1 colocalized with each other
The PS1 and APP-BP1 antibodies used in the above exper-
iments are well documented. To examine the interaction
of APP-BP1 and PS1 even further, primary neurons were
labelled with mouse anti-myc antibody for myc-APP-BP1
and rabbit anti-PS1-C. As shown in Figure 2, APP-BP1 and
PS1 were colocalized as indicated by the orange color
when the two colors were merged. Similar results were
also obtained using the mouse anti-APP-BP1 and the rab-
bit anti-PS1 (AB5308) antibodies for the endogenous
APP-BP1 and PS1 (not shown). APP-BP1 appeared to co-
localize with PS1 outside the nucleus. Future analyses
may determine the precise location of these interactions.
Suppression of APP-BP1 by siRNAs lead to the 
accumulation of APP and APP-CTFs, and a dramatic 
increase in the levels of cell-associated Aβ42
We showed that APP-BP1 interacted with PS1 (Fig. 1 &2),
indicating that APP-BP1 might functionally regulate γ-
secretase activity. To determine if APP-BP1 affected the γ-
secretase cleavage of APP, we examined the effect of APP-
BP1 siRNAs in APP processing by western blots and Aβ
ELISA in primary neurons. Neurons were infected with
human APP695 virus together with the APP-BP1 siRNA
virus. As shown in Figure 3A, the endogenous APP-BP1 in
primary neurons was suppressed by APP-BP1 siRNAs but
not by the missense siRNAs. γ-Tubulin levels did not
change under these experimental infection conditions.
In another set of experiments, the human APP695 was
expressed in primary neurons with or without a siRNA
virus (Fig. 3B). Immunoblots with the anti-APP antibody,
369, showed that APP siRNAs suppressed APP protein
expressions. In contrast, in the presence of APP-BP1 siR-
NAs, APP was increased, opposite to the effect of APP siR-
NAs. The control missense siRNAs did not have major
effects on APP metabolism. Quantitative western blot
APP-BP1, PS1 and nicastrin co-immunoprecipitated and co-migrated in br i  protein extractsFi ur  1
APP-BP1, PS1 and nicastrin co-immunoprecipitated 
and co-migrated in brain protein extracts. A. APP-BP1 
co-immunoprecipitated with PS1 in brain lysates. Adult rat 
brain lysates were immunoprecipitated with the rabbit anti-
PS1 antibody (middle lane), or a non-related antibody (rabbit 
anti-cyclin B1). The blot was probed with the anti-APP-BP1 
antibody, BP339 or with rabbit anti-nicastrin. Anti-PS1 specif-
ically precipitated APP-BP1 and nicastrin which were absent 
in control lanes. This experiment has been repeated three 
times. B. PS1 co-precipitated with APP-BP1 in membrane 
fractions. Proteins extracted from membrane fractions were 
precipitated with the APP-BP1 antibody, BP339 or with the 
BP339 preimmune serum (pre) or beads alone. The blot was 
probed with the PS1 antibody (AB5308) for PS1-FL and PS1-
CTF, or with antibodies against PS1-NTF or nicastrin. C. 
APP-BP1 co-migrated with PS1 in glycerol gradient of mem-
brane protein extracts isolated from adult rat brains. Brain 
membrane proteins were subjected to glycerol gradient cen-
trifugation. Proteins in equal volumes from each fraction 
were resolved by SDS-PAGE gels. The blots were incubated 
with specific antibodies followed by ChemiGlow detections. 
Fractions 2 to 4 contain the majority of each protein ana-
lyzed. APP-BP1 was found to co-migrate with PS1 (FL, NTF, 
and CTF), and nicastrin. The location of β-catenin was also 
shown in the glycerol gradient. BioRad Precision Plus protein 
standards are shown on the right. PS1-CTF identified by 
AB5308 antibody was verified by a PS1-C-specific antibody 
(D).Page 3 of 12
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APP-BP1 siRNA-expressing neurons (Fig. 3D, n = 3, p <
0.003, two-tail t-Test).
In neurons infected with APP695 with or without the
APP-BP1 siRNA virus, APP-CTF levels were analyzed in
16% Tris-Tricine gels using the antibody 369. A represent-
ative blot is shown in Fig. 3C. Based on a two-tail t-Test,
APP-CTFs significantly accumulated in the APP-BP1
siRNA-expressing cells (n = 4, p < 0.001) (Fig. 3D). The
accumulation of APP-CTFs in these experimental condi-
tions was similar to the effect of the γ-secretase inhibitor
L685459 (Sigma) (Fig. 3C). Increases in APP-CTFs have
been shown in familial APP mutants [20] and in PS1
experimental deletion mutants [21]. Accumulation of
APP and APP-CTFs in our experiments indicated that APP-
BP1 might modulate APP cleavage by the γ-secretase.
To determine if APP-BP1 affected the γ-secretase cleavage
of APP, neurons were infected with APP695 with or with-
out a siRNA virus. The levels of cell-associated and
secreted Aβ40 and Aβ42 was analyzed by ELISA. Aβ levels
were normalized to the sample that expressed only APP695
(100%) (Fig. 4A&B). In the presence of APP-BP1 siRNAs,
the cell-associated Aβ42 was dramatically increased, but
Aβ40 was elevated to a much lesser extent (Fig. 4A&B, left,
respectively). Increases in cell-associated Aβ42 were
accompanied by higher Aβ42 secretions in the medium
(Fig. 4A, right). Aβ40 secretion was largely unaffected (Fig.
4B, right). These results obtained with the ELISA kits from
Biosource International were confirmed in independent
experiments using the Aβ ELSIA kits from the Genetics
Company. These data suggested that APP-BP1 might spe-
cifically inhibit APP cleavage into Aβ42.
APP-BP1 expression resulted in a reduction of rat 
endogenous APP but did not affect APLPs in primary 
neurons
We showed that suppression of the rat endogenous APP-
BP1 caused a dramatic increase in cell-associated Aβ42
(Fig. 4A, left) in addition to the accumulation of APP and
CTFs (Fig. 3B–D). To further validate these APP-BP1
shRNA experiments, we inspected if overexpression of
APP-BP1 in primary neurons would inhibit APP process-
ing opposite to the effect of APP-BP1 suppression by siR-
NAs. In Fig. 5, a myc-tagged human APP-BP1 was
expressed in primary neurons and the rat endogenous
APP levels were analyzed. A representative western blot
was shown in Fig. 5B. Quantitative western blot analyses
showed that APP was significantly reduced in mycAPP-
BP1 expressing neurons (Fig. 5C). The APP-like proteins
can also undergo γ-secretase cleavage [22]. However, there
were no significant changes in the levels of the APP-like
proteins, APLP1 or APLP2, due to mycAPP-BP1 expression
in these neurons. The decreases in the rat endogenous
APP-CTFs were not analyzed because they were difficult to
detect, unlike in experimental conditions where the
human APP was expressed in primary neurons (Fig. 3C).
The decrease in APP and not in APLPs indicated that APP-
BP1 specifically affected APP cleavage although APLPs,
especially APLP2, are highly homologous to APP. During
our analyses, we found that APP-BP1 also interacted with
APP upstream of C31 near the inner plasma membrane
insertion site (see Additional file 1, Fig. 1) [1,8]. The long
APP-BP1 and PS1 molecules were colocalized in primary neuronsFigure 2
APP-BP1 and PS1 molecules were colocalized in primary neurons. Primary neurons were  fixed, permeablized, 
blocked and stained with 9E10 for mycAPP-BP1 and the  rabbit anti-PS1 (AB5308).  Primary antibodies were coupled to Alexa 
Fluor 594  and Alexa Fluor 488 goat secondary antibodies. The images presented were obtained under a 40× objective with a 
Nikon confocal microscope using the EZ-C12.20 scanning program. Independent experiments using DAPI staining along with 
the above two antibodies did not show nuclear co-localization of APP-BP1 and PS1 (not shown).Page 4 of 12
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be necessary for the specificity of APP-BP1.
APP-BP1 expression inhibited cell-associated Aβ levels
We showed that APP-BP1 expression specifically down-
regulated rat endogenous APP (Fig. 5), but it is difficult to
detect the rat endogenous Aβ levels. Here we examined if
expressing human APP-BP1 can reduce the levels of cell-
associated Aβ in primary neurons that co-expressed
human APP695 Equal amount of cell extracts was precipi-
tated by the antibody 6E10 and the precipitates were ana-
lyzed by western blotting using the antibody 4G8. The
locations of Aβ peptides were determined by the standard
on the same blot. Semi-quantitative analyses of Aβ levels
from four co-ip experiments showed that APP-BP1 expres-
sion significantly reduced Aβ levels compared to the con-
trol (vector virus p1005+) (Fig. 5D. p < 0.04, one tail t-
Test). A representative blot is shown as an insert (Fig. 5D).
Downregulation of APP-BP1 by siRNAs in primary neurons affected APP processingFigure 3
Downregulation of APP-BP1 by siRNAs in primary 
neurons affected APP processing. A. APP-BP1 was sup-
pressed by APP-BP1 siRNAs but not by missense siRNAs. 
Primary neurons were infected with 0.5 IU of siRNA virus 
per cell. Equal amount of proteins extracted by RIPA buffer 
was analyzed by western blotting for APP-BP1 expression. 
The same blot was reprobed with a mouse anti-γ-tubulin 
antibody. No obvious changes in γ-tubulin levels were 
detected. BP1siRNA, APP-BP1siRNA; mis-siRNA, misssense 
siRNA. B. Suppression of APP-BP1 by siRNAs caused 
increases in exogenous human APP. Primary neurons were 
infected with or without APP and siRNA constructs. APP 
was probed with the antibody 369. The same membrane was 
reprobed for γ-tubulin with a mouse anti-γ-tubulin for load-
ing controls. In each sample, 10 μg of proteins was analyzed. 
The data is representative of three-independent experi-
ments. C. APP-BP1 siRNA inhibited APP-CTF processing in 
primary neurons expressing human APP. APP-CTFs were 
resolved on 16% Tris-Tricine gels. The blot was probed with 
369. A representative of 4 independent experiments was 
shown. The intervening lanes between mis-siRNA and 
L685459 were cut off. D. APP-BP1 siRNA expression signifi-
cantly blocked APP processing. Quantitative western blot 
analyses of 3 (APP) or 4 (CTF) independent experiments 
were carried out using two-tail t-Test (APP: BP1siRNA vs 
mis-siRNA, p < 0.003; CTF: BP1siRNA vs mis-siRNA, p < 
0.001).
Suppression of APP-BP1 protein expression by APP-BP1 siR-NAs in primary neurons resulted in increases of intracellular Aβ42Figu  4
Suppression of APP-BP1 protein expression by APP-
BP1 siRNAs in primary neurons resulted in increases 
of intracellular Aβ42. Intracellular (from 50 μg of protein 
from lysates) and secreted (from 1/15 volume of conditioned 
medium) Aβ42 in primary neurons were determined by 
Aβ42 ELISA (A). Intracellular (from 50 μg of protein) and 
secreted (from 1/30 volume of medium of conditioned 
medium) Aβ40 in primary neurons was determined by Aβ40 
ELISA (B). The amount of Aβ in samples that expressed APP 
without any siRNA interference was used as 100% of Aβ 
production. All the rest of the samples were normalized to 
this sample, and presented as percentage in respective exper-
imental conditions. Data is representative of three independ-
ent experiments. BP1siRNA, APP-BP1 siRNA; NegsiRNA, 
Negative siRNA (Stratagene).Page 5 of 12
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immuno-western blots mainly because very little Aβ40
was detected in the blots, probably because Aβ40 was very
unstable in neuron extracts in contrast to Aβ42. In ELISA
assays we noticed that Aβ40 was dramatically reduced
after even one freeze-and-thaw cycle.
APP-BP1 downregulated PS1-CTF stability in primary 
neurons
Our data suggest that APP-BP1 functionally interacts with
PS1 by inhibiting Aβ42 levels. PS1-CTF has been shown to
regulate Aβ42 production through stability and endocyto-
sis [23]. Moreover, APP-BP1-activated neddylation plays a
pivotal role in protein turnover. Here the levels of PS1-
CTF were examined in primary neurons overexpressing
APP-BP1. Quantitative analyses revealed that PS1-CTF
was significantly downregulated by APP-BP1 (Fig. 6B, n =
3, p < 0.049, one-tail t-Test). A representative blot was
shown in Fig. 6A. In contrast, even though nicastrin co-
precipitated with APP-BP1 (Fig. 1), its levels remained
unchanged with APP-BP1 expression (Fig. 6A). γ-Tubulin
expression was used as the loading control (Fig. 6A).
Discussion
One of the hallmarks of AD pathogenesis is Aβ aggrega-
tion and deposition in the extra cellular space in the brain
[24-26]. Increased Aβ42/Aβ40 ratios seem to initiate the
disease process [27,28]. The necessity of Aβ42 for amyloid
deposition is further demonstrated in mice expressing
Aβ42 but not in those expressing Aβ40 [29]. However, evi-
dence also suggests that decreases in Aβ40 may perturbs
the Aβ42/Aβ40 ratio triggering the deposition of Aβ [30-
32]. Familial AD APP mutations produce different levels
of Aβ42, with the highest amount of Aβ42 produced by
the London mutation or mutations close to the γ cleavage
site in APP [33,34].
In this report, we provided evidence that APP-BP1 might
inhibit Aβ42 levels by interacting with PS1. We showed
that APP-BP1 co-precipitated and co-migrated with the
PS1 and nicastrin in brain protein extracts (Fig. 1). Native
APP-BP1 and PS1 molecules were colocalized in primary
neurons (Fig. 2). The significance of the APP-BP1/PS1
interaction was further investigated in primary neurons
using HSV vector-mediated gene transfers. Downregula-
tion of APP-BP1 by siRNAs in primary neurons revealed
that APP-BP1 might regulate APP processing into Aβ42
(Fig. 4). Further, APP-BP1 overexpression in primary neu-
rons resulted in the specific downregulation of rat endog-
enous APP, and also appeared to downregulate Aβ42 (Fig.
5). We also analyzed the potential mechanisms of APP-
BP1-mediated Aβ42 inhibition and found that APP-BP1
regulated PS1-CTF levels in neurons. Together, our data
suggest that APP-BP1 inhibits Aβ42 by modulating γ-
APP-BP1 expression increased APP processing in primary neuronsFigure 5
APP-BP1 expression increased APP processing in 
primary neurons. A. Expression of myc-tagged APP-BP1. 
Equal amount of total proteins from neurons infected with 
APP-BP1 virus or p1005+ virus was analyzed by western 
blotting using the mouse ant-myc antibody, 9E10. B. APP-
BP1 overexpression downregulated rat endogenous APP. 
APP expression from 15 μg of proteins was analyzed by 
immunoblots using the anti-APP antibody 369. The amount 
of γ-tubulin from the same blot was reprobed with a mouse 
anti-γ-tubulin antibody. Representative blots from the same 
experiments are shown. C. Quantitative western blot analy-
ses revealed that APP-BP1 significantly downregulated the 
endogenous APP but not APLPs in neurons overexpressing 
myc APP-BP1. mycAPP-BP1 expression significantly 
decreased APP levels compared to the sample infected with 
the vector (p1005+) (n = 4, p < 0.02, one-tail t-Test). APLP1 
levels stayed the same, and APLP2 did not showed a signifi-
cant change by t-Tests (n = 3, p = 0.1, one tail t-Test). D. 
RIPA buffer soluble protein extracts from primary neurons 
co-expressing APP-BP1 and APP695 or p1005+ and APP695 
were precipitated with 6E10 followed by western blot analy-
ses using 4G8. Mean levels of Aβ is presented in the graph (n 
= 4, p < 0.04). A representative of 4 independent blots was 
shown as an insert.Page 6 of 12
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illustrated in the diagram (Fig. 7).
All four known γ-secretase components are membrane
proteins including the regulatory subunit CD147 recently
reported [35-38]. The predicted molecular weight of APP-
BP1 is 59 kDa. APP-BP1 is not a membrane protein, but it
undergoes at least two types of posttranslational modifi-
cations that may enable membrane association [1,8]. We
have shown before that an APP-BP1 (about 65 kD) specif-
ically migrates to the lipid-enriched fraction [8]. Our new
data demonstrated that the 65 kDa APP-BP1 was present
in brain membrane fractions co-migrating with the γ-
secretase complex, suggesting that a membrane-associated
and modified APP-BP1 modulated γ-secretase activity and
inhibited cell-associated Aβ42 production. APP-BP1 is
extremely unstable. We could not unequivocally demon-
strate that it was the 65 kDa APP-BP1 that co-precipitated
with PS1 because this 65 kDa form could be easily
reduced to the 59 kDa form during frequent handing in
the experiments. However, glycerol gradient centrifuga-
tion (Fig. 1C) and sucrose gradient centrifugation [8] both
showed that the 65 kDa APP-BP1 co-migrated with PS1.
Further, our data suggest that APP-BP1 downregulates
Aβ42 production by regulating PS1-CTF degradation,
which indicates that APP-BP1 may affect PS1 trafficking.
Determining the cellular locations of APP-BP1 and PS1
interaction may shed light on if APP-BP1 plays a role in
PS1 trafficking. Further, APP-BP1 may facilitate PS1-CTF
degradation by neddylation and ubiquitination. These
two likely processes mediated by APP-BP1 may co-exist in
a membrane compartment. A previous study showed that
the small ubiquitin-like protein Sumo-2 (not Nedd8 or
ubiquitin) regulates APP processing in transfected 293T
cells [39]. However, this study did not specifically analyze
Aβ42. APP-BP1 does have potential Sumo modification
sites which may affect its function in APP processing.
Detailed analyses of APP-BP1 post-translational modifica-
tions may yield clues to the partitioning of APP-BP1 to
specific membrane compartments where APP-BP1 may
inhibit Aβ42 genesis.
In addition to inhibiting Aβ42 genesis, our findings sug-
gest that APP-BP1 may mediate Aβ42 degradation inside
the cell. This is suggested by the observation that the accu-
mulation of cell-associated Aβ42 greatly exceeded the
amount of Aβ42 secreted into the medium in the presence
of APP-BP1 siRNAs. Intraneuronal Aβ accumulation has
been observed in AD [40-43], Down's syndrome
[40,42,44-46], and AD mouse models [41,47-49] and is
implied in AD pathogenesis (for reviews, see [25,50,51].
Due to the known function of the APP-BP1 pathway in
protein degradation, APP-BP1 might also play a pivotal
role in intraneuronal Aβ homeostasis.
APP-BP1 expression decreases PS1-CTF stability in primary neuronsFigure 6
APP-BP1 expression decreases PS1-CTF stability in 
primary neurons. Primary neurons were infected with 
mycAPP-BP1 or p1005+ vector virus for 14 hrs before har-
vesting. Levels of the rat endogenous PS1 and PS1-CTF were 
examined by western blots. A representative PS1-CTF blot 
was shown in A. The same blot was reprobed with the rabbit 
anti-nicastrin or mouse anti-γ-tubulin antibodies after strip-
ping. B, Quantitative western blot analyses show significant 
reduction of PS1-CTF in APP-BP1 expressing neurons (n = 3, 
p < 0.049, one tail t-Test).Page 7 of 12
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activates neddylation and results in neuronal death due to
cell cycle reactivation [2,8]. Increases in APP-BP1 would
also make it more available for post-translational modifi-
cations and the subsequent membrane partitioning with
PS1 to inhibit Aβ42 genesis. Our previous data show that
the predominant effect of APP-BP1 overexpression is to
promote cell cycle progression in somatic cells. However,
in primary neurons, APP-BP1 mainly induces neuronal
death due to forced cell cycle re-entry. In these conditions,
although APP-BP1 may downregulate Aβ42 production, it
does not seem sufficient to overcome cell cycle-induced
neuronal apoptosis due to APP-BP1 overexpression. We
suspect that the Triton-soluble, cytosolic 59 kDa APP-BP1
may activate neddylation associated with cell cycle regula-
tion which is normally inhibited by factors such as ASPP2
[52]. However, the Triton-soluble 59 kDa APP-BP1 is not
increased in AD and therefore APP-BP1 may not be a
direct factor inducing cell cycle events in AD [8]. This new
hypothesis agrees with the observation that APP-BP1 is
naturally expressed in high levels in hippocampal neu-
rons in vivo [1]. Moreover, the Triton-insoluble and SDS-
soluble APP-BP1, presumably the 65 kDa form, appeared
to be downregulated in the brain during normal aging
(See Additional file 1, Fig. 2). The combined evidence sug-
gests that the increase of the 65 kDa APP-BP1 in AD is
beneficial to neurons by inhibiting Aβ42 genesis and
points to a potential therapeutic strategy of upregulating
APP-BP1 modification.
Whether or not genetic variants of APP-BP1 are associated
with inherited susceptibility to AD remains to be ana-
lyzed. Since APP-BP1 appears to regulate Aβ42 produc-
tion, AD-susceptible APP-BP1 variants may exist.
However, APP-BP1 has critical functions in somatic cell
survival due to its role in neddylation. Any APP-BP1
mutations that result in neddylation dysfunction are
likely to be prenatal lethal. If these two functions are inde-
pendent of each other, those APP-BP1 variants which sup-
port neddylation and do not severely affect neuronal
differentiation would be detectible. How neddylation and
Aβ42 inhibition by APP-BP1 might be inter-related in
neurons needs to be investigated further.
Conclusion
In this report, we documented evidence that APP-BP1
plays a role in APP processing, especially in Aβ42 inhibi-
tion, in neuronal cells. First, we showed that APP-BP1
interacted with the APP processing enzyme, PS1, in brain
tissues. Secondly, APP-BP1 suppression by siRNAs trig-
gered a dramatic increase in Aβ42 levels in primary neu-
rons. Thirdly, increased APP-BP1 expression specifically
inhibited APP processing into Aβ in neurons. Lastly, we
examined the potential mechanisms of APP-BP1 function
in Aβ42 downregulation and provided evidence that APP-
BP1 might downregulate Aβ42 levels by facilitating PS1-
CTF degradation. Our data also suggest that a modified
form of APP-BP1 interacts with PS1 in a membrane com-
partment where it plays a role in Aβ42 inhibition. Future
research may determine how this pathway can provide
therapeutic targets for Alzheimer's disease.
Methods
Antibodies
The following antibodies were used: rabbit anti-PS1
(AB5308) and 22C11 (Chemicon), BP339 [2], mouse
anti-APP-BP1 (BD Transduction Lab), 6E10 and 4G8 (Sig-
net), rabbit anti-cyclin B1 (Santa Cruz), 9E10 (ATCC),
rabbit anti-APLP1 and rabbit anti-APLP2 (both from Cal-
biochem), rabbit anti-nicastrin, rabbit anti-β-catenin and
mouse anti-γ-tubulin (all three from Sigma). The follow-
ing antibodies are generous gifts from others: rabbit 369
antibody against APP cytoplasmic tail from Dr. Sam
Diagram of APP-BP1-mediated Aβ42 inhibitionFigure 7
Diagram of APP-BP1-mediated Aβ42 inhibition. 
Potential pathways through which APP-BP1 inhibits Aβ42 are 
presented with a question mark.Page 8 of 12
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rabbit anti-PS1-NTF from Dr. Huaxi Xu.
Co-immunoprecipitation (Co-ip)
Co-ip of APP-BP1 with PS1 was performed using adult
Sprague Dawley Rat brain lysates. Briefly, rat brain tissues
were isolated and solublized in a buffer containing 20
mM Tris, pH 7.5, 1 mM MgCl2, 125 mM NaCl, 2%
CHAPS, and the protease inhibitor cocktail (1:250) from
Sigma. The rabbit anti-PS1 antibody (AB5308) was preb-
ound to protein G agarose by rocking in the lysis buffer for
two hours at 4°C. The controls were beads alone or beads
prebound to the rabbit anti-cyclin B1. The antibody-
bound beads were washed 1× with the lysis buffer and
added to the soluble brain extracts. The mixture was
rocked for 2 hours on ice. The immune complex was col-
lected by centrifugation at 4°C, washed 4× with the lysis
buffer, and resolved on a 7.5% SDS-PAGE gel. The protein
was transferred to a nitrocellulose membrane, blocked
with 6% milk/PBS, and probed with the rabbit anti-APP-
BP1 antibody, BP339 [2] or rabbit anti-nicastrin.
Co-precipitation of PS1 with APP-BP1 was carried out
essentially as described above except that the brain mem-
brane fraction proteins were used. To prepare the mem-
brane fraction, rat brains were first homogenized for 15
strokes in a Dunce homogenizer in Buffer 1 containing 10
mM Tris, pH7.4, 150 mM NaCl, 5 mM EDTA, pH 8, and
250 mM sucrose plus the protease and phosphatase inhib-
itor cocktail (1 mM PMSF, 1 mM NaVO4, 5 mM iodoa-
cetamide, 10 mM β-glycerol phosphate, 50 mM sodium
pyrophosphate, and 50 mM NaF). The homogenate was
centrifuged for 10 min at 1500 × g at 4°C and the pellet
was discarded. The supernatant was saved and centrifuged
again for 30 min at 20800 × g at 4°C. After centrifugation,
the pellet was washed once with the Wash Buffer (1 M
KCl, 20 mM HEPES, pH 7.2, 2 mM EGTA, 2 mM EDTA, 2
mM DTT, and the inhibitor cocktail). Proteins in the pel-
let were extracted (membrane fraction) for 1 hr on ice
with the Extraction Buffer (20 mM Tris, pH8, 1 mM
MgCl2, 125 nN NaCl, 2% CHAPS, and the inhibitor cock-
tail). These membrane proteins were cleared by centrifu-
gation at 20800 × g at 4°C for 1 hr before the primary
antibody was added. The membrane fraction was incu-
bated with BP339 pre-bound to protein G beads, beads
alone, or BP339 pre-immune antibody. The immune
complex was incubated at 37°C for 10 min before loading
on to an SDS-PAGE gel. The blot was probed with rabbit
anti-PS1 (AB5308), rabbit anti-PS1-NTF, or rabbit anti-
nicastrin.
Glycerol velocity gradient centrifugation
Membrane fractions from adult Sprague Dawley rat brains
were isolated as described above. The post-nuclear, puri-
fied membranes were extracted with 2% CHAPS, 100 mM
KCl, 20 mM Hepes at pH 7.2, 2 mM EGTA, 2 mM EDTA,
2 mM DTT containing protease inhibitor cocktail for 1 hr
on ice. The soluble membrane proteins were applied to
the top of a glycerol gradient. The glycerol gradient proto-
col was as described previously with minor modifications
[53,54]. Briefly, 1 ml of membrane protein extracts was
applied to the top of an 11 ml 10–40% linear glycerol gra-
dient containing 25 mM Hepes pH 7.2, 150 mM NaCl and
0.5% CHAPS. Gradients were centrifuged for 15 hrs at
210,000 × g at 4°C. One ml fractions were collected from
top to bottom. After adding SDS loading buffer to 24 μl of
each fraction, the samples were heated for 10 min at
100°C before loading on to SDS-PAGE gels. The blots
were incubated with antibodies against PS1 (AB5308),
PS1-NTF, PS1-CTF (PS1-C) [19], APP-BP1 (BP339) [2],
nicastrin, or β-catenin followed by ChemiGlow detection
(Alpha Innotech).
Primary neurons
Primary neurons were isolated from E18 rat embryonic
brain cortices. The cortices were gently triturated with a
fine-tipped transfer pipette right after dissection. Cells
were immediately plated in the neurobasal medium sup-
plemented with 2% B27 (both from Invitrogen), 0.5 mM
glutamine, 1% FBS, 1% equine serum, and 1× of penicil-
lin/streptomycin (all from Sigma) at a density of 3 or 4 ×
106 per 60 mm dish or 4 × 105 per well in 24-well plate.
The medium was replaced with the complete fresh neuro-
basal medium at 1.5 hours post plating. To maintain the
culture, half of the medium was replaced with fresh
medium every three days. Cells were used on day 6 or 7
after plating.
siRNA expressions in primary neurons
siRNAs were expressed via the short hairpin RNA (shRNA)
vector, pHSVGET, in primary neurons. To construct the
pHSVGET vector, we inserted the tRNAval promoter
sequence [55,56] into the SalI-digested pHSVprPUC-
eGFP (a gift from Dr. JF Neumaier) [57]. shRNAs are nor-
mally processed by the Dicer enzyme into siRNAs inside
the cell. Each shRNA duplex was designed with the Invit-
rogen web site BLOCK-iT™ RNAi Designer program using
the TCAAGAG as the loop sequence. The siRNA targeting
sequences for BP1 were (a) 5'-GGTAGATATCCAGGAG-
TATCT-3' or (b) 5'-GCATTTCTTCGAGTGGTAAGA-3'. The
APP siRNAs were directed at (a) 5'-GTGATGCCCTTCTCG
TTCCTG-3' or (b) 5'-GCAGAAGATGTGGGTTCAAAC-3'.
The control random siRNAs are misssense, (a) 5'-
CTTCATAA GGGGCATAGCTA-3' or (b) Negative siRNA
(Stratagene). All constructs were sequenced for verifica-
tion before HSV-1 viral packaging. The (a) group of siRNA
vectors was used in most of the experiments, but the
results were verified with the (b) group of siRNA vectors.Page 9 of 12
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HSV-1 is a neural tropic virus whose genome does not
integrate with the host genome. All HSV-1 viruses were
packaged using the 2-2 cell line as described by Lim et al
[58]. The infectious unit (IU) of each siRNA virus in the
pHSVGET vector was determined by infecting primary
neurons for 15 hours with serial diluted stocks. After fixa-
tion in 4% paraformaldehyde for 20 min at room temper-
atures, eGFP positive cells were visualized by fluorescence
microscopy. The mycAPP-BP1 open reading frame from
pHSVprPUC [8] was transferred into the p1005+ vector.
The p1005+ vector was the same as pHSVprPUC-eGFP
except that the multiple cloning sites were modified. The
mycAPP-BP1/p1005+ and the p1005+ vector were pack-
aged into HSV-1 and titered by eGFP expression. The
expression of mycAPP-BP1 was verified by western blots
using the anti-myc antibody 9E10.
Neuron infection and analyses of APP and APLPs by 
western blots
Primary neuronal cultures maintained in 60 mm dishes
were infected at day 7 post plating at 1 IU per cell for pro-
tein expression, or at 0.5 IU per cell for siRNA knockdown
analyses. At 14 to 15 hours after infection, cells were
washed with cold 1× PBS and lysed in RIPA buffer (0.5%
sodium deoxycholate, 0.1% SDS, 1% NP40, 5 mM EDTA,
150 mM NaCl, and 50 mM Tris-HCL, pH 8.0) containing
the protease inhibitor cocktail (1:250), 1 mM PMSF, 5
mM iodoacetamide, 50 mM NaF, 1 mM Na3VO4, and 10
mM β-glycerol phosphate (all from Sigma). The lysates
were briefly sonicated. After protein assays using the
Pierce BCA kit, equal amount of proteins were boiled in
the SDS sample loading buffer and analyzed with SDS-
PAGE gels.
Aβ ELISA and INF-γ ELISA
Aβ42 and Aβ40 ELISAs were performed using the condi-
tioned medium as well as cell lysates prepared with RIPA
buffer as described [59], according to the manufacturer's
protocols (Biosource International). Cell-associated
(from 50 μg of protein) and secreted (from 1/15 volume
of conditioned medium) Aβ42 in primary neurons were
determined by Aβ42 ELISA. Cell-associated (from 50 μg of
protein) and secreted (from 1/30 volume of medium of
conditioned medium) Aβ40 in primary neurons was
determined by Aβ40 ELISA. The amount of Aβ in samples
that expressed APP without any siRNAs was used as 100%
of Aβ production to normalize all the other samples in
respective experimental conditions. The Aβ ELISA assay
was repeated with the Aβ ELISA kits from The Genetics
Company. INF-γ ELISA was performed on 50 μg of protein
for intracellular INF-γ or on 1/15 volume of conditioned
medium for secreted INF-γ using protocols provided by
the manufacturer (Biosource International). The pHS-
VGET vector-based siRNA transfer into primary neurons
did not induce INF-γ response – no intracellular or
secreted INF-γ was detected by IFN-γ ELISA compared to
IFN-γ standards (Biosource International) (data not
shown). Therefore, it is unlikely that the reduced protein
expression observed by specific siRNAs was caused by
stress-induced global shutdown of gene transcriptions.
Immunoprecipitation and western blot analyses of Aβ
Primary neurons expressing human APP695 along with
mycAPP-BP1 or vector control was lysed in Extraction
Buffer (0.5% sodium deoxycholate, 0.1% SDS, 20 mM
EDTA, 150 mM NaCl, 50 mM Tris, pH 8) containing pro-
tease and phosphatase inhibitor cocktail. Cell extract (150
ug) was subjected to immunoprecipitation with 6E10
using a protocol as described [60]. The immune complex
pulled down by 6E10 was boiled in sample loading buffer
for 10 min and resolved on a bicine-Tris gel (15% T/5%
C) with 8 M urea according to Klafki et al. [61]. The blot
was boiled in 1 × PBS for 3 minutes before incubation
with the 4G8 antibody overnight. Standard Aβ40 and
Aβ42 peptides were purchased from American Peptide.
Quantitative western blot and statistical analyses
Quantitative western blot analyses were based on densit-
ometry of usually three or more independent experiments
using the Scion Image software (Scion Corporation).
Band densities were measured on exposures of blots
within a linear range. The specific protein levels per lane
in equal area of space were determined by deducting the
background per individual lane and by normalizing that
density to the amount of γ-tubulin per respective lane.
One tail or two tail (more stringent) t-Tests for two sam-
ples assuming unequal variance were performed on the
normalized data using the EXCEL data analysis tool
(Microsoft). The statistical significance was set at p < 0.05.
Colocalization of APP-BP1 and PS1 by fluorescence 
microscopy
Primary neurons grown on glass coverslips were fixed in
4% paraformaldehyde for 40 minutes at room tempera-
ture. Cells were then permeablized in 0.1% Triton X-100
for 15 minutes and blocked in Blocking Buffer (1% BSA
and 10% normal goat serum in 10 mM phosphate-buff-
ered saline) for 15 minutes. Cells were then incubated
with the primary antibodies against PS1 (AB5308, 1:250,
v/v) and 9E10 or mouse anti-APP-BP1 (1 ug/100 ul) for 2
hours. Cells were then washed twice with the Blocking
Buffer and incubated for 1 hr with the secondary antibod-
ies: Alexa Fluor 488 goat anti-rabbit and Alexa Fluor 594
goat anti-mouse (Molecular Probes, 1:300, v/v). Images
were collected under a 40× objective using a Nikon confo-
cal microscope (D-Eclipse C1) or a Nikon epifluorescence
microscope (Eclipse E600).Page 10 of 12
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